Link to the University of Pittsburgh Homepage
Link to the University Library System Homepage Link to the Contact Us Form

Is adjuvant radiotherapy warranted in resected pT1-2 node-positive rectal cancer?

Peng, J and Li, X and Ding, Y and Shi, D and Wu, H and Cai, S (2013) Is adjuvant radiotherapy warranted in resected pT1-2 node-positive rectal cancer? Radiation Oncology, 8 (1).

Published Version
Available under License : See the attached license file.

Download (340kB) | Preview
[img] Plain Text (licence)
Available under License : See the attached license file.

Download (1kB)


Background: Stage T1-2 rectal cancers are unlikely to have lymph node metastases and neoadjuvant therapy is not routinely administered. Postoperative management is controversial if lymph node metastases are detected in the resected specimen. We studied the outcomes of patients with pT1-2 node-positive rectal cancer in order to determine whether adjuvant radiotherapy was beneficial. Methods: We conducted a retrospective analysis of 284 patients with pathological T1-2 node-positive rectal cancer from a single institution. Outcomes, including local recurrence (LR), distant metastasis (DM), disease free survival (DFS) and overall survival (OS), were studied in patients with detailed TN staging and different adjuvant treatment modalities. Results: The overall 5-year LR, DM, DFS and OS rates for all patients were 12.5%, 32.9%, 36.4% and 76.8%, respectively. Local control was inferior among patients who received no adjuvant therapy. Patients could be divided into three risk subsets: Low-risk, T1N1; Intermediate-risk, T2N1 and T1N2; and High-risk, T2N2. The 5-year LR rates were 5.3%, 9.8% and 26.4%, respectively (p = 0.005). In High-risk patients, addition of radiotherapy achieved a 5-year LR rate of 9.1%, compared 34.8% without radiotherapy. Conclusions: In our study, we provide the detailed outcomes and preliminary survival analysis in a relatively infrequent subset of rectal cancer. Three risk subsets could be identified based on local control for pT1-2 node positive rectal cancer. Postoperative treatment needs to be individualized for patients with pT1-2 node-positive rectal cancer. © 2013 Peng et al.; licensee BioMed Central Ltd.


Social Networking:
Share |


Item Type: Article
Status: Published
CreatorsEmailPitt UsernameORCID
Peng, J
Li, X
Shi, D
Wu, H
Cai, S
Date: 19 December 2013
Date Type: Publication
Journal or Publication Title: Radiation Oncology
Volume: 8
Number: 1
DOI or Unique Handle: 10.1186/1748-717x-8-290
Schools and Programs: School of Public Health > Biostatistics
Refereed: Yes
Date Deposited: 02 Dec 2016 18:31
Last Modified: 02 Feb 2019 13:55


Monthly Views for the past 3 years

Plum Analytics

Actions (login required)

View Item View Item